Dabigatran Etexilate Mesylate is a direct thrombin inhibitor (Factor IIa) used as an oral anticoagulant to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat DVT/PE. Upon administration, it is converted into Dabigatran, its active form. Dabigatran Etexilate Mesylate is a key player in the NOAC segment, offering an effective alternative to warfarin with fewer dietary restrictions and minimal monitoring.

Explore Royal Pharma as your potential partner for Dabigatran Etexilate Mesylate API.